{"id":"75b0a48e-9bcf-513a-99ef-55891c027e5b","stable_key":"09b23d0d-35e2-51ff-b1aa-b4f9227e4fa2:isoleucine-iars-low-substrate","predicate":"supports","statement":"IARS-deficient patient fibroblasts had reduced residual aminoacylation activity and greater growth sensitivity to low isoleucine.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"0e4a52c5-9771-507a-b99b-4cf0874667cf","mechanism_event_label":"Low substrate can expose the limited reserve of a faulty enzyme.","subject":{"id":"fe83b156-e71e-5193-a958-0665af0e55ae","slug":"iars1","display_name":"Human cytosolic isoleucyl-tRNA synthetase / IARS1","entity_type_key":"protein"},"object":{"id":"05eabeb5-2593-5544-bdcb-9056f9563ddd","slug":"human-iars1-fibroblast-growth","display_name":"Growth of IARS1-deficient human fibroblasts","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"0e4a52c5-9771-507a-b99b-4cf0874667cf","stable_key":"09b23d0d-35e2-51ff-b1aa-b4f9227e4fa2:isoleucine-iars-low-substrate-event","event_type":"observed_relationship","label":"Low substrate can expose the limited reserve of a faulty enzyme.","description":"IARS-deficient patient fibroblasts had reduced residual aminoacylation activity and greater growth sensitivity to low isoleucine.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"fe83b156-e71e-5193-a958-0665af0e55ae","slug":"iars1","display_name":"Human cytosolic isoleucyl-tRNA synthetase / IARS1","entity_type_key":"protein"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"05eabeb5-2593-5544-bdcb-9056f9563ddd","slug":"human-iars1-fibroblast-growth","display_name":"Growth of IARS1-deficient human fibroblasts","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"c85b327e-f132-5d9a-8e4b-c2976fcc0373","slug":"isoleucine","display_name":"L-Isoleucine","entity_type_key":"small_molecule"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"availability_state","value_text":"machinery_impairment","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null},{"dimension":"evidence_access","value_text":"Primary abstract","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Patient-derived human fibroblasts tested across isoleucine concentrations.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Do not assign the study temperature sensitivity in LARS/FARSB to IARS without evidence.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"L-Isoleucine collection; species, compartment, exposure, co-substrates and manipulation remain explicit.","comparator":null,"unit":null,"notes":"","entity":{"slug":"isoleucine","display_name":"L-Isoleucine","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"Low substrate can expose the limited reserve of a faulty enzyme.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Treatment of ARS deficiencies with specific amino acids. · 2021 · https://pubmed.ncbi.nlm.nih.gov/34194004/ · DOI 10.1038/s41436-021-01249-z","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"trigger_kind","value_text":"machinery_impairment","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null}],"evidence":[{"id":"3c1c0a80-e92c-5d57-8f02-24c0849adb24","evidence_kind":"source_excerpt","locator":"Lines 130-136","start_line":130,"end_line":136,"excerpt":"## isoleucine-iars-low-substrate\nLow substrate can expose the limited reserve of a faulty enzyme.\nIARS-deficient patient fibroblasts had reduced residual aminoacylation activity and greater growth sensitivity to low isoleucine.\nModel: Patient-derived human fibroblasts tested across isoleucine concentrations.\nLimitations: Do not assign the study temperature sensitivity in LARS/FARSB to IARS without evidence.\nEvidence access: Primary abstract\nTreatment of ARS deficiencies with specific amino acids. · 2021 · https://pubmed.ncbi.nlm.nih.gov/34194004/ · DOI 10.1038/s41436-021-01249-z","model_system":"Patient-derived human fibroblasts tested across isoleucine concentrations.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Original curation paraphrase; evidence access and experimental limitations specified.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"4b00f118-00fd-5cef-be97-13125eb958e9","stable_key":"import-09b23d0d-35e2-51ff-b1aa-b4f9227e4fa2","title":"L-Isoleucine: transport, translation, catabolism and cross-nutrient mechanisms (2026-09-19)","document_type":"imported_text","citation_label":"AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text.","file_path":"","sha256":"2058ff0da379586994e7fda6ae0086c60fa3173542bfaf1fb3871ad3e09f9c6c","revision_id":"f32192d4-9913-5d35-acbc-cf90ff17995e","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}